Clinical pharmacology, efficacy, and safety aspects of sphingosine-1-phosphate receptor modulators
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Clinical pharmacology, efficacy, and safety aspects of sphingosine-1-phosphate receptor modulators
Authors
Keywords
-
Journal
Expert Opinion on Drug Metabolism & Toxicology
Volume 12, Issue 8, Pages 879-895
Publisher
Informa UK Limited
Online
2016-06-02
DOI
10.1080/17425255.2016.1196188
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial
- (2016) Fred Lublin et al. LANCET
- Combination of the Immune Modulator Fingolimod With Alteplase in Acute Ischemic StrokeCLINICAL PERSPECTIVE
- (2015) Zilong Zhu et al. CIRCULATION
- A Novel Gradual Up-Titration Regimen Mitigates The First-Dose Effects Of Ponesimod, A Selective S1p1 Receptor Modulator
- (2015) M. Hoch et al. CLINICAL THERAPEUTICS
- Effects of Therapeutic and Supratherapeutic Doses of Siponimod (BAF312) on Cardiac Repolarization in Healthy Subjects
- (2015) Kasra Shakeri-Nejad et al. CLINICAL THERAPEUTICS
- Pharmacokinetic and pharmacodynamic interaction of siponimod (BAF312) and propranolol in healthy subjects
- (2015) Shibadas Biswal et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Three different up-titration regimens of ponesimod, an S1P1receptor modulator, in healthy subjects
- (2015) Michael W. Scherz et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Effect of ceralifimod (ONO-4641) on lymphocytes and cardiac function: Randomized, double-blind, placebo-controlled trial with an open-label fingolimod arm
- (2015) Sonja Krösser et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Defects of High-Density Lipoproteins in Coronary Artery Disease Caused by Low Sphingosine-1-Phosphate Content
- (2015) Katherine Sattler et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Fingolimod effects on left ventricular function in multiple sclerosis
- (2015) Vittorio Racca et al. Multiple Sclerosis Journal
- Biocomparison of Three Formulations of the S1P1 Receptor Modulator Ponesimod in Healthy Subjects
- (2015) Pierre-Eric Juif et al. Drugs in research & development
- Fingolimod effects on left ventricular function in multiple sclerosis
- (2015) Vittorio Racca et al. Multiple Sclerosis Journal
- Development and Function of Protective and Pathologic Memory CD4 T Cells
- (2015) Shafqat Ahrar Jaigirdar et al. Frontiers in Immunology
- Peripheral Blood T Cell Dynamics Predict Relapse in Multiple Sclerosis Patients on Fingolimod
- (2015) Zi-Ye Song et al. PLoS One
- Effect of Ponesimod, a Selective S1P1Receptor Modulator, on the QT Interval in Healthy Individuals
- (2014) Matthias Hoch et al. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
- Clinical pharmacology of ponesimod, a selective S1P1 receptor modulator, after uptitration to supratherapeutic doses in healthy subjects
- (2014) M. Hoch et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- Differential effects of ponesimod, a selective S1P1receptor modulator, on blood-circulating human T cell subpopulations
- (2014) Daniele D'Ambrosio et al. IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY
- Multiple-dose tolerability, pharmacokinetics, and pharmacodynamics of ponesimod, an S1P1receptor modulator: Favorable impact of dose up-titration
- (2014) P. Brossard et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial
- (2014) T. Olsson et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Population pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator
- (2014) Andreas Krause et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial
- (2014) Andrea Vaclavkova et al. LANCET
- Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2014) Peter A Calabresi et al. LANCET NEUROLOGY
- Effects of Ethnicity and Sex on the Pharmacokinetics and Pharmacodynamics of the Selective Sphingosine-1-Phosphate Receptor 1 Modulator Ponesimod: A Clinical Study in Japanese and Caucasian Subjects
- (2014) Maribel Reyes et al. PHARMACOLOGY
- Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1receptor modulator, in the first-in-human study
- (2013) Patrick Brossard et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- The Immunosuppressant FTY720 Prolongs Survival in a Mouse Model of Diet-induced Coronary Atherosclerosis and Myocardial Infarction
- (2013) Guanying Wang et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- Macrophages in inflammatory multiple sclerosis lesions have an intermediate activation status
- (2013) Daphne YS Vogel et al. Journal of Neuroinflammation
- Fingolimod: Direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy
- (2013) Aran Groves et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study
- (2013) Krzysztof Selmaj et al. LANCET NEUROLOGY
- Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy
- (2013) G Francis et al. Multiple Sclerosis Journal
- Therapeutic Use of a Selective S1P1 Receptor Modulator Ponesimod in Autoimmune Diabetes
- (2013) Sylvaine You et al. PLoS One
- FTY720 Ameliorates Acute Ischemic Stroke in Mice by Reducing Thrombo-Inflammation but Not by Direct Neuroprotection
- (2013) Peter Kraft et al. STROKE
- Sphingosine kinase and sphingosine 1-phosphate in the heart: A decade of progress
- (2012) Joel S. Karliner BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS
- Dose titration of BAF312 attenuates the initial heart rate reducing effect in healthy subjects
- (2012) Eric Legangneux et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate
- (2012) P Gergely et al. BRITISH JOURNAL OF PHARMACOLOGY
- Efficacy and immunomodulatory actions of ONO-4641, a novel selective agonist for sphingosine 1-phosphate receptors 1 and 5, in preclinical models of multiple sclerosis
- (2012) T. Komiya et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Systematic Review and Meta-Analysis of the Efficacy of Sphingosine-1-Phosphate (S1P) Receptor Agonist FTY720 (Fingolimod) in Animal Models of Stroke
- (2012) Junfeng Liu et al. INTERNATIONAL JOURNAL OF NEUROSCIENCE
- Clinical Pharmacokinetics of Fingolimod
- (2011) Olivier J. David et al. CLINICAL PHARMACOKINETICS
- Placebo-controlled study of the effects of fingolimod on cardiac rate and rhythm and pulmonary function in healthy volunteers
- (2011) Robert Schmouder et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Memory/effector (CD45RBlo) CD4 T cells are controlled directly by IL-10 and cause IL-22–dependent intestinal pathology
- (2011) Masahito Kamanaka et al. JOURNAL OF EXPERIMENTAL MEDICINE
- The Selective Sphingosine 1-Phosphate Receptor 1 Agonist Ponesimod Protects against Lymphocyte-Mediated Tissue Inflammation
- (2011) L. Piali et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis
- (2011) M. Mehling et al. NEUROLOGY
- Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M
- (2011) C. Christoffersen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Absorption and Disposition of the Sphingosine 1-Phosphate Receptor Modulator Fingolimod (FTY720) in Healthy Volunteers: A Case of Xenobiotic Biotransformation Following Endogenous Metabolic Pathways
- (2010) M. Zollinger et al. DRUG METABOLISM AND DISPOSITION
- Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis
- (2010) Volker Brinkmann et al. NATURE REVIEWS DRUG DISCOVERY
- Fingolimod is a potential novel therapy for multiple sclerosis
- (2010) Orhan Aktas et al. Nature Reviews Neurology
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
- (2010) Ludwig Kappos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
- (2010) Jeffrey A. Cohen et al. NEW ENGLAND JOURNAL OF MEDICINE
- International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid Receptor Nomenclature
- (2010) J. Chun et al. PHARMACOLOGICAL REVIEWS
- Lymphatic endothelial cell sphingosine kinase activity is required for lymphocyte egress and lymphatic patterning
- (2009) Trung H.M. Pham et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Activation of Sphingosine 1-Phosphate Receptor-1 by FTY720 Is Neuroprotective After Ischemic Stroke in Rats
- (2009) Yu Hasegawa et al. STROKE
- Sphingosine-1-phosphate signaling and biological activities in the cardiovascular system
- (2008) Y TAKUWA BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS
- The effect on heart rate of combining single-dose fingolimod with steady-state atenolol or diltiazem in healthy subjects
- (2008) John M. Kovarik et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis
- (2008) M. Mehling et al. NEUROLOGY
- B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis
- (2008) Stephen L. Hauser et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation